Paul A. Mahon, EVP & General Counsel of United Therapeutics, executed a stock transaction on 12/19/2024. Mahon exercised 7,700 shares of Common Stock at $163.30 per share through a derivative security conversion, immediately followed by a sale of the same number of shares at $360.16 each.The total value of the disposed shares amounted to $2,773,232. After these transactions, Mahon's direct ownership in United Therapeutics decreased to 36,710 shares. The transactions were completed on the same day, indicating a planned exercise-and-sell strategy.This insider activity provides insight into executive stock operations at United Therapeutics, potentially reflecting the company's stock-based compensation practices and the executive's personal financial management decisions.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, executed a stock transaction on 12/19/2024. Mahon exercised 7,700 shares of Common Stock at $163.30 per share through a derivative security conversion, immediately followed by a sale of the same number of shares at $360.16 each.The total value of the disposed shares amounted to $2,773,232. After these transactions, Mahon's direct ownership in United Therapeutics decreased to 36,710 shares. The transactions were completed on the same day, indicating a planned exercise-and-sell strategy.This insider activity provides insight into executive stock operations at United Therapeutics, potentially reflecting the company's stock-based compensation practices and the executive's personal financial management decisions.